Rare disease focus Quoin Pharmaceuticals concentrates on rare and orphan diseases with a pipeline targeting conditions like Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, and Epidermolysis Bullosa, presenting clear niche opportunities for specialty care channels and patient advocacy partnerships.

US and Europe expansion The company plans to establish a sales infrastructure to commercialize products in the United States and Europe, signaling near-term opportunities for regional market access initiatives, distributor collaborations, and localized regulatory readiness.

Strategic licensing Quoin seeks strategic licensing partnerships for territories beyond its core markets, offering potential collaboration avenues with regional pharma players to accelerate growth, co-development, and multi-territory distribution.

Innovative delivery Ongoing development of novel rapamycin formulations using Invisicare technology to enhance delivery and efficacy creates a potential add-on value proposition for dermatology-focused clinicians and payers seeking improved treatment options for rare dermatoses.

Strategic partnerships & funding Recent financings and collaboration news, including a partnership with Maxim Group as placement agent and a research agreement with University College Cork, indicate active capital markets activity and potential for co-development or sponsored research deals to advance late-stage programs.